26 Jan GENESIS Tech Transfer Boost incorporates a new investment partner, PINONO S.L.
• GENESIS Tech Transfer Boost is an investment vehicle created in 2022 that invests in the field of Biomedicine.
• The three founding partners, GENESIS Biomed, FI Group and Crowd4Ventures, have been joined by PINONO S.L.
• This new incorporation will increase the number of projects in which to invest, consolidating GENESIS Tech Transfer Boost as a relevant player in the private financing of early-stage projects in the embryonic phase.
GENESIS Tech Transfer Boost, an investment vehicle managed by GENESIS Biomed, is adding a new partner. The vehicle was created in April 2022 with the aim of detecting and investing in early-stage projects in the biomedical sector, whether from hospitals or academic centres, following in the footsteps of its predecessor GENESIS Ventures. To the €1M commitment from founding partners GENESIS Biomed, FI Group and Crowd4Ventures, PINONO S.L. is now added with a €200,000 commitment.
In the words of Lian Mariné, majority partner of PINONO S.L., “We are delighted to be an investment partner of a vehicle in the field of Biomedicine, such as GENESIS Tech Transfer Boost. This field, which a few years ago was unknown to most investors, is becoming an attractive sector where the emergence of Deep Tech and new technologies are bringing about a revolution with a high impact on people’s quality of life“.
In the words of Josep Lluís Falcó, CEO of GENESIS Biomed, “the incorporation of a new partner is good news for the vehicle, in particular, and for the biomedical ecosystem in general. The expansion of the fund will allow us to increase the number of early projects in which to invest. This investment will allow the projects to mature so that in the future they can access venture capital investments that will allow them to reach the market“.
The vehicle invests tickets of between €25,000 and €100,000 depending on the nature of each project and its needs, and even provides for the possibility of investing in the pre-constitution phase of projects.
During 2023 GENESIS Tech transfer Boost made two investments. The first investment was carried out in March with the investment of a €100,000 ticket in the IiSPV spin-off, RetinaReadRisk. The biotech company has developed a mobile system based on artificial intelligence to predict diabetic retinopathy. GENESIS Biomed has acted as a Venture Building platform in this spin-off: in addition to acting as investor and fund manager, it has been assuming the functions of administrator and interim CEO of the company, helping to raise new public funds, and coordinating the regulatory development of the product, and identifying the new CEO recently hired in the company.
The second investment was made in April, where a €25,000 ticket was invested in the biotech company Spinally Medical. Spinally Medical is a company that has developed and protected a spinal cord stimulation system for the treatment of low back and legs pain (LBP).
In addition to these two investments, three other fundraising processes have been initiated in the last quarter of 2023 and will most likely be closed during the first-second quarter of 2024.
The objective of the vehicle is, in a first phase, to continue to carry out investments in biomedicine projects for the remaining three years to later, in a second phase, find exit scenarios that allow the recovery of the investment with its corresponding multiples.
About PINONO S.L.
PINONO was born from the desire to diversify the family business network, which to date has been based in the real estate and agri-food sectors. The aim is to participate in projects whose main focus is the substantial improvement of people’s health and wellbeing. The participation of PINONO S.L. in the investment vehicle GENESIS Tech Transfer Boost is an opportunity to enter a relevant sector such as the biomedical one.
About GENESIS Biomed
Founded in 2017, GENESIS Biomed is a company specialising in the genesis of biomedical companies that develop innovative solutions to improve people’s health and quality of life. Headquartered in Barcelona and with offices in Madrid and Valencia, GENESIS Biomed is a reference player at national level and with a clear international vocation that has a team of 14 highly qualified, specialised, and experienced professionals. The company, which is firmly committed to entrepreneurship and business development in the biomedical sector, is a leading consultancy firm in the sector in Spain for researchers, research centres and investors who want to develop spin-offs and start-ups.
For more information about GENESIS Biomed, please contact:
firstname.lastname@example.org / +34 93 403 58 53
About FI Group
International consulting firm with more than 20 years of experience and 38 offices around the world. The Group is made up of more than 1,400 professionals, 80% of whom are graduates and doctors in different areas of knowledge. With a 100% client focus, they work to become a strategic partner in the management of R&D&I financing, from the development of the project’s idea to its commercialisation.
Investment club set up in 2021 with the aim of democratising professional investment in specialised funds.